CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

Intellia Therapeutics, Inc.’s NTLA share price has surged by 5.05%, which has investors questioning if this is right time to ...

Among other items, Intellia announced that it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and will discontinue development of NTLA-3001, which will result in the ...

Meanwhile, Truist Securities has adjusted its price target for Intellia from $90 to $50, maintaining a Buy rating due to concerns over a competitive landscape, despite the company’s progress with its ...

said it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and discontinue development of NTLA-3001, which will result in the company cutting around 27% of its workforce.

and NTLA-2002 for hereditary angioedema (a rare swelling condition). The company is also creating cancer and autoimmune therapies through partnerships. For Q4 that ended December 31, 2024 ...

Intellia is also engaged in a strategic restructuring to extend its operational runway into 2027, as it advances its pipeline, including the NTLA-2002 treatment, which has shown promising ...